Concepedia
Statistics
Publications
17
Citations
2K
H-Index
16
Active since
2003
Affiliations
Boehringer Ingelheim (United States)(Current)
Pfizer (United States)
Bristol-Myers Squibb (United States)
Eli Lilly (United States)
United States Military Academy
Diann Blanset is an author at Boehringer Ingelheim (United States) specializing in immunology, pharmacy, and cancer immunotherapy.
Publications per year
2003–2022
<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
Changyu Wang, Kent Thudium, Minhua Han et al. · Cancer Immunology Research · 2014 · 592 citations
Life Sciences, Immunology, Oncology +17
Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
Stephen M. Ansell, Steven M. Horwitz, Andreas Engert et al. · Journal of Clinical Oncology · 2007 · 251 citations
Medicine, Oncology, Pharmacology +16
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark Selby, John Engelhardt, Robert J. Johnston et al. · PLoS ONE · 2016 · 228 citations · Full text
Medicine, Immunology, Oncology +17
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
Susanne Hipp, YT Tai, Diann Blanset et al. · Leukemia · 2016 · 228 citations · Full text
Medicine, Immunology, Oncology +14
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
Anna Hryniewicz, Adriano Boasso, Yvette Edghill‐Smith et al. · Blood · 2006 · 166 citations · Full text
Life Sciences, Immunology, Molecular Biology +16
1–5 of 17